Cantargia Advances Nadunolimab Development Following TRIFOUR Trial Results, Secures Otsuka Partnership for CAN10 Program
核心洞察
Cantargia (搜索) plans to advance nadunolimab development in pancreatic ductal adenocarcinoma (搜索) (PDAC (搜索)) based on strong safety data from the TRIFOUR trial, despite awaiting full results for triple-negative breast cancer (搜索) decisions.
The company secured a partnership with Otsuka (搜索) for the CAN10 program, with Otsuka taking over responsibility and costs from Q4 2025, including potential access to additional CANxx platform programs.
For triple-negative breast cancer (搜索), Cantargia (搜索) aims to demonstrate survival improvements over the reference chemotherapy arm's 11-month benchmark through ongoing overall survival analysis.
Cantargia (搜索) AB reported strategic developments in its oncology pipeline during its Q2 2025 earnings call, highlighting progress with its lead antibody nadunolimab and a significant partnership agreement with Otsuka (搜索) for the CAN10 program.
TRIFOUR Trial Results Drive Strategic Decisions
The company's TRIFOUR study results are shaping future development plans for nadunolimab, particularly in different cancer indications. Interim CEO Damian Marron indicated that while the company will wait for full results before deciding next steps specifically for triple-negative breast cancer (搜索) (TNBC (搜索)), the strong safety data encourages advancement in other indications.
"The strong safety data encourages us to move forward with nadunolimab in other indications, particularly PDAC (搜索), where there is a strong association with IL1RAP (搜索) expression," Marron stated during the earnings call.
For the triple-negative breast cancer (搜索) program, Cantargia (搜索) is targeting survival improvements over existing standards. The company aims to exceed the reference chemotherapy arm's 11-month survival rate. "We aim to see an improvement over the reference chemotherapy arm alone. Once we have the overall survival results, we will benchmark them against the current competitive landscape to assess our position," Marron explained.
Otsuka Partnership Advances CAN10 Development
Cantargia (搜索) has secured a partnership with Otsuka (搜索) for its CAN10 program, representing a significant milestone for the company's pipeline diversification. The agreement includes both CAN10 and 3G5 (搜索), with Otsuka assuming responsibility and costs for progressing the CAN10 program from the transaction closing expected in Q4 2025.
Chief Business Officer Antonius Berkien confirmed that "Otsuka (搜索) will take over the responsibility and costs for progressing the CAN10 program from the closing of the transaction, which is expected in Q4 2025."
The partnership extends beyond the initial programs, with Otsuka (搜索) holding an option to explore additional programs from Cantargia (搜索)'s CANxx platform. "We have flexibility to develop in areas of interest, and Otsuka has an option to explore additional programs from our CANxx platform," Berkien noted.
Leadership Transition and Strategic Direction
The company announced the appointment of Dr. Hilde Steineger as CEO, bringing extensive biotech industry experience to guide Cantargia (搜索)'s strategic direction. Marron highlighted her qualifications, stating, "Dr. Hilde Steineger brings a broad and deep experience as a biotech executive, with strong business development skills, financial analysis expertise, and a wide range of industry contacts. Her profile is ideal for leading Cantargia forward."
Ongoing Clinical Data Analysis
Cantargia (搜索) has prespecified subgroup analyses ongoing for the TRIFOUR study, with plans to present additional data at scientific conferences or through company announcements. "We have prespecified subgroup analyses ongoing, and we expect to provide data on those, potentially at a scientific conference or through an announcement," Marron confirmed.
The company's strategic focus on pancreatic ductal adenocarcinoma (搜索) reflects the strong association between this cancer type and IL1RAP (搜索) expression, the target of nadunolimab. This indication represents a significant opportunity given the limited treatment options and poor prognosis associated with PDAC (搜索).